Asciminib Roll-over Study
Asciminib Roll-over Study
Recruiting · NCT04877522 · Registry updated 2026-07-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Asciminib Roll-over Study | Carcinogenesis, Cell Transformation, Neoplastic, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 4 | 2026-07-06 | NCT04877522 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Novartis Pharmaceuticals | 432 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Medical College of Wisconsin | Milwaukee | United States | 483 |
| Memorial Sloan Kettering | New York | United States | 5 |
| Michigan Med University of Michigan | Ann Arbor | United States | 1 |
| Oregon Health Sciences University | Portland | United States | 33 |
| Texas Oncology | Dallas | United States | 7 |
| Uni Of TX MD Anderson Cancer Cntr | Houston | United States | 7 |